[Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation].
OBJECTIVE
To study the clinical outcome of patients with fms-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML) treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) and to explore the potential prognostic factors to patients' survival including transplant types or disease status.


METHODS
A total of 314 AML patients in our center from October 2006 to October 2012 were retrospectively analyzed, among whom, 54 patients were defined with FLT3-ITD positive. Survival rates and treatment-related mortality were further analyzed.


RESULTS
For all 54 FLT3-ITD positive patients, the 3-year overall survival (3-OS) rate was 56% and 3-year leukemia-free survival (3-LFS) rate was 47%. The outcome of haplo-identical HSCT was similar as that of sibling donors (3-OS rate: 60% vs 54%; 3-LFS rate: 54% vs 45%, respectively) . There were 47 patients who received transplantation in first complete remission (CR1) . The other 7 patients were of disease relapse or in CR2 before transplantation. Not surprisingly, patients in CR1 had better prognosis than those in non-CR1.


CONCLUSIONS
Allo-HSCT is an effective treatment for AML patients with FLT3-ITD positive mutation. The survival outcome of haplo-identical HSCT was comparable with that of sibling donors. Relapse of AML was the dominant factor related to the mortality of FLT3-ITD positive AML patients after allo-HSCT.
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Zhen
Z
Yang
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Hong
H
Tian
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Yang
Y
Xu
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Huiying
H
Qiu
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Suning
S
Chen
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Aining
A
Sun
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China. Email: wudepei@medmail.com.cn.
Depei
D
Wu
D000293:Adolescent; D000328:Adult; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D012189:Retrospective Studies; D020080:Tandem Repeat Sequences; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3